Login
Companies $CNMD
$49.35 +$0.00 (0.0%) After hours
CONMED Corp logo

CONMED Corp

conmed.com

What Do They Do?

Sells minimally invasive surgery, endoscopic and smoke-removal devices to surgeons and other healthcare professionals, as well as orthopedic surgery products.

How Do They Make Money?

General-surgery buyers pay for products when they ship. Orthopedic products are also paid for at shipment; CONMED additionally earns a fee from MTF tied to its customer invoices for promoting sports medicine tissue, with services provided over time.

revenue
SegmentShareRevenue
Orthopedic Surgery
Sold outright

42%
FY2022: 44%
General Surgery
Sold outright

58%
FY2022: 56%

Who Are Their Customers?

Hospitals, surgery centers and other healthcare institutions buy directly or through medical specialty distributors; internationally, local dealers and direct in-country sales teams serve customers. Some hospitals use independent medical device distributors for inventory management.

Do Revenues Turn Into Profits?

Yes. It kept 3 cents of every revenue dollar as net income in FY2025 and turned 11 cents into free cash flow.

Operating income, FY2025
7% of revenue
▼ −49% vs FY2024 ($200.3M, 15%)
Net income, FY2025
3% of revenue
▼ −64% vs FY2024 ($132.4M, 10%)
Free cash flow, FY2025
11% of revenue
▼ −2% vs FY2024 ($153.9M, 12%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −1%
vs $337.9M in Q3 FY2025
Net income
▲ +592%
vs $2.9M in Q3 FY2025
General Surgery share of revenue vs 59.1% in Q3 FY2025
  • Jul 29, 2026 Updated full-year financial guidance Raised adjusted diluted EPS guidance to $4.48–$4.60 and updated the full-year net sales range to $1,358–$1,373 million.
  • Jun 17, 2026 Appointed John Gallagher as chief financial officer Gallagher's appointment takes effect July 15, 2026; Todd Garner remains with the company in an advisory capacity through November 2, 2026.

Growing. Revenue grew 36% in 4 years, from $1B in FY2021 to $1.4B in FY2025, about 8% a year.

Gastroenterology product exit The older report described a broad portfolio of gastroenterology products. The latest report says CONMED intends to exit the remaining gastroenterology products after ending its Gore biliary-device distribution agreement.

Revenue over time
Orthopedic Surgery General Surgery
$2B$1B$0

Who Do They Compete With?

Competes with Smith & Nephew, Arthrex, Stryker, Johnson & Johnson, Zimmer Biomet, Globus Medical, Treace Medical Concepts, Medtronic, Olympus, ERBE Elektromedizin, Applied Medical Resources, Boston Scientific, Cook Medical, Merit Medical, STERIS, Cantel Medical, Cardinal Health, and 3M

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support